Arax Advisory Partners’s Cardiff Oncology CRDF Stock Holding History
Bought
Maintained
Sold
Other funds holding CRDF
Arax Advisory Partners's CRDF Position: Q2 2026 in Review
Arax Advisory Partners increased its Cardiff Oncology (CRDF) stake by 2,159% in Q2 2026, buying an estimated $11.7K and bringing the position to 7,681 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #4332.
Arax Advisory Partners first reported a position in CRDF in Q2 2025 and has held it in 5 quarters since. 104 funds tracked by Wall St. Rank hold CRDF as of Q2 2026.
- Arax Advisory Partners held 7,681 shares of Cardiff Oncology worth $10K as of Q2 2026.
- Arax Advisory Partners bought 7,341 Cardiff Oncology shares in Q2 2026, an estimated $11.7K.
- Cardiff Oncology made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #4332 holding.
- Arax Advisory Partners first reported a position in Cardiff Oncology in Q2 2025 and has held it in 5 quarters since.
- 104 funds tracked by Wall St. Rank held Cardiff Oncology as of Q2 2026.
Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.